Crosshair Therapeutics develops an artificial intelligence platform that utilizes computational modeling to design chain-like therapeutics for cancer, neurodegenerative diseases, and longevity. The platform encodes these therapeutics for delivery using custom-engineered gene therapy vectors, enabling healthcare institutions to target complex diseases effectively.
Funding
Funding not disclosed
Founders
Product
Problem
Targeting complex diseases like cancer and neurodegenerative disorders requires therapeutics capable of addressing multiple disease mechanisms simultaneously. Traditional drug development struggles to create treatments that can effectively modulate multiple targets with high specificity and minimal off-target effects.
Solution
Crosshair Therapeutics is developing an AI-driven platform for designing multi-specific, chain-like therapeutics. The platform uses computational modeling to identify optimal therapeutic designs that can simultaneously target multiple disease pathways. These therapeutics are then encoded for delivery using custom-engineered gene therapy vectors, enabling precise and efficient targeting of complex diseases at the genetic level. This approach aims to improve treatment efficacy and reduce side effects by delivering highly specific, multi-targeted therapies.
Target Audience
The primary target audience includes healthcare institutions and pharmaceutical companies focused on developing advanced therapies for cancer, neurodegenerative diseases, and age-related disorders.
Features
- AI-driven platform for computational design of multi-specific therapeutics
- Chain-like therapeutic architecture for simultaneous targeting of multiple disease pathways
- Custom-engineered gene therapy vectors for targeted delivery
- Computational modeling to optimize therapeutic designs and minimize off-target effects